lacutamab

Monoclonal antibody

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

Featured evidence outside this drug's tracked markets:NCT04984837 · Peripheral T-Cell Lymphoma · Phase 2 · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Cutaneous T-Cell Lymphoma
Other / comorbidity
NCT04984837 · The Lymphoma Academic Research Organisation
2021-10-05 – 2028-04-30 · Peripheral T Cell Lymphoma, Relapse/Recurrence
What this study did
Phase 1 (2)
Cutaneous T-Cell Lymphoma
NCT02593045 · Innate Pharma
2015-10 – 2020-04 · Cutaneous T-Cell Lymphoma
What this study did
Other / comorbidity
NCT05321147 · Innate Pharma
2022-03-17 – 2024-02-08 · Peripheral T Cell Lymphoma
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT03322618 · Assistance Publique Hopitaux De Marseille
2017-12-18 – 2019-09-17 · Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS)
What this study did

Competitive landscape

This drug's own stage for Cutaneous T-Cell Lymphoma: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lacutamab: this drugPhase 2Monoclonal antibodyKIR3DL2not yet gradedNo reviewed efficacy summary in this indication
Brentuximab VedotinApprovedAntibody–drug conjugateAnti-CD30 antibody-drug conjugatePartial signal
NCT01578499: Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4) (Each Cycle until disease progression, death End of treatment (Median overall follow-up 38.8 months)): Brentuximab Vedotin 54.7 percentage of participants (95% CI 42.5 to 66.9) | Methotrexate or Bexarotene 12.5 percentage of participants (95% CI 4.4 to 20.6)
RomidepsinApprovedSmall moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
VorinostatApprovedSmall moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow lacutamab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
April 2028 (1)
Phase 2Peripheral T Cell Lymphoma, Relapse/RecurrenceActive not recruiting
Est. primary completion 2028-04-30 · NCT04984837 · CT.gov ↗
What to watch

See the full readout calendar ↗